TY  - JOUR
AU  - Giorgio, Antonio
AU  - Gatti, Pietro
AU  - Matteucci, Paolo
AU  - Giorgio, Valentina
PY  - 2018
TI  - Ablative therapies for intrahepatic cholangiocarcinoma
JF  - Hepatobiliary Surgery and Nutrition; Vol 7, No 3 (June 21, 2018): Hepatobiliary Surgery and Nutrition
Y2  - 2018
KW  - 
N2  - Among the 3 sub-types of cholangiocarcinoma (CH), [intrahepatic CH, hylar (CH) and extrahepatic (CH)], intrahepatic cholangiocarcinoma (ICC) accounts for up 8–10% of cholangiocarcinomas and 10–20% of all primary liver tumors (1). Interestingly, the occurrence of ICC on cirrhosis is increasing in the last years (2). Diagnosis of ICC mainly relies on histologic findings obtained with imaging guided biopsy when a hepatic lesion, usually single (small or large), is occasionally discovered in a healthy liver or in a cirrhotic liver during surveillance for hepatocellular carcinoma (HCC).
UR  - https://hbsn.amegroups.org/article/view/18696